KMC
STLN

Kirr Marbach & Co’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Kirr Marbach & Co’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,725
Closed -$331K – 58
2024
Q1 		$331K Buy
+2,725
New +$5.18K 0.08% 49

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.62B AUM 18.42% 1-Year Est. Return
BFM
Boston Financial Management Boston, Massachusetts $3.31B AUM 19.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kirr Marbach & Co's STLN Position: Q2 2024 in Review

Kirr Marbach & Co sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2024, closing a stake of 2,725 shares — an estimated $331K sold.

Kirr Marbach & Co first reported a position in STLN in Q1 2024 and held it in 1 quarter. The position peaked at $331K in Q1 2024. 39 funds tracked by Wall St. Rank hold STLN as of Q2 2024.

  • Kirr Marbach & Co reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Kirr Marbach & Co sold 2,725 Starling Oncology Institute, Inc. Common Stock shares in Q2 2024, an estimated $331K.
  • Kirr Marbach & Co first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Kirr Marbach & Co's Starling Oncology Institute, Inc. Common Stock position peaked at $331K in Q1 2024.
  • 39 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2024.

Based on Kirr Marbach & Co's 13F filing for Q2 2024, filed 22 Jul 2024.